<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733616</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-08-02</org_study_id>
    <secondary_id>EudraCT Nº: 2008-001825-32</secondary_id>
    <nct_id>NCT00733616</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status</brief_title>
  <official_title>Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine efficacy and safety of combination therapy with&#xD;
      adjusted-dose docetaxel-oxaliplatin-capecitabine in patients with advanced gastric&#xD;
      adenocarcinoma and intermediate general status.(defined as ECOG 2 or weight loss 10-25% or&#xD;
      older that 70 years and no comorbidities nor functional dependency nor geriatric syndrome)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2008-2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>2008-2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS), time to treatment failure (TTF), overall survival and dose intensity</measure>
    <time_frame>2008-2011</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOX: Docetaxel, oxaliplatin, Capecitabine</intervention_name>
    <description>Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1&#xD;
Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1&#xD;
Capecitabine 625 mg/m2, bid, oral, continuous&#xD;
6 cycles, every 3 weeks&#xD;
Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. informed consent signed&#xD;
&#xD;
          2. Histological or cytological adenocarcinoma confirmation carcinoma on the&#xD;
             esophago-gastric union or stomach (type I, II and III Siervent) metastatic or relapsed&#xD;
&#xD;
          3. measurable disease (following RECIST criteria)&#xD;
&#xD;
          4. older or equal 70 years old&#xD;
&#xD;
          5. Intermediate general status defined as at least one of the following characteristics:&#xD;
             performance status (ECOG) = 2, weight loss ponderada between 10 and 25% in the last 3&#xD;
             months&#xD;
&#xD;
          6. life expectancy superior to 12 weeks&#xD;
&#xD;
          7. adequate hematological function: Neutrophils ≥1.50x109, platelets ≥100x109, Hemoglobin&#xD;
             ≥10 g/dl&#xD;
&#xD;
          8. adequate liver function: Liver function (total bilirubine &lt; 2 NV; GOT y GPT &lt;3 NV (&lt; 5&#xD;
             NV in case of liver metastasis; Alkaline phosphatase &lt;3 NV ))&#xD;
&#xD;
          9. Adequate renal function: renal function (Creatinine clearance &gt; 50mL/min), based on&#xD;
             Cockroff - Gault. In case Creatinine clearance is &lt; 50 ml/min, a test in urine will be&#xD;
             done in 24 hours and if the value is &gt; 50 ml/min, the patient could be eligible for&#xD;
             the study&#xD;
&#xD;
         10. Potential fertile women negative pregnancy test in serum or urine, 10 days prior the&#xD;
             first study dose given&#xD;
&#xD;
         11. Use an adequate contraceptive method (postmenopausal women should be amenorrheic at&#xD;
             least 12 months previous the study to be considered as not potentially fertile&#xD;
             (VN:upper limit on normal laboratory values)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. non measurable lesion as only disease evidence&#xD;
&#xD;
          2. previous chemotherapy treatment for advance disease. It wont´t be consider as&#xD;
             exclusion criteria if chemo or radiotherapy has been given for localized disease and&#xD;
             finished more than 1 year ago. In caso os only measurable disease in the radiated&#xD;
             area, progressive disease has to be documented previous to the inclusion&#xD;
&#xD;
          3. functional dependency&#xD;
&#xD;
          4. hypersensitivity to Docetaxel, oxaliplatin or capecitabine&#xD;
&#xD;
          5. previous serious adverse events or unexpected to fluoropirimidin treatment and /or&#xD;
             patients with proved deficit in dehidropirimidin deshidrogenase (DPD)&#xD;
&#xD;
          6. patients classified as &quot;weak or fragile&quot;&#xD;
&#xD;
               1. dependency on one or more of the daily activities following the daily activity&#xD;
                  scale from Katz&#xD;
&#xD;
               2. three or more comorbitities of the following: congestive cardiac insufficiency,&#xD;
                  cardiac valvulopathy, coronaripathia, chronic pulmonary disease (obstructive or&#xD;
                  restrictive), cerebrovascular disease, diabetes, concomitant neoplasms, collagen&#xD;
                  vascular disease, chronic hetopathy and incapacitate arthritis&#xD;
&#xD;
               3. presence of geriatric syndromes: moderate-severe dementia, stress delirium&#xD;
                  (urinary respiratory infection); moderate-severe depression that interfere in the&#xD;
                  habitual daily life; frequent falls (3 or more monthly); be disattended; urinary&#xD;
                  incontinence, without stress, infection, diuretics or prostatic hyperplasia;&#xD;
                  fecal incontinence without diarrhea or laxative; osteoporotic fracture of long&#xD;
                  bone or vertebral squash&#xD;
&#xD;
          7. Cardiac concomitant present:&#xD;
&#xD;
               1. Symptomatic auriculoventricular arrhythmia history, and /or&#xD;
&#xD;
               2. Congestive cardiac insufficiency non controlled by drugs, and / or&#xD;
&#xD;
               3. Myocardial infarct 12 months previous the inclusion, and /or&#xD;
&#xD;
               4. Symptomatic ischemic cardiopathy&#xD;
&#xD;
          8. active infectious process ((leukocytes superior to 12 x 109/l or fever upper to 38º,&#xD;
             it is required thorax X:ray, hemoculture and urine culture 5 days previous to the&#xD;
             inclusion)&#xD;
&#xD;
          9. severe or bad controlled concomitant disease&#xD;
&#xD;
         10. neoplastic history (except skin basocellular or in-situ cervical carcinoma properly&#xD;
             treated) in the last 5 years&#xD;
&#xD;
         11. patients with any other medical or surgical important problem that, in the&#xD;
             investigator opinion, could not allow to follow the treatment&#xD;
&#xD;
         12. not able to fulfill the protocol and follow-up&#xD;
&#xD;
         13. being involve in any investigational trial with any drug within 4 weeks prior the&#xD;
             study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Rivera, MD; phD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Marques de Valdecilla. Santander. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced gastric adenocarcinoma</keyword>
  <keyword>docetaxel</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>capecitabine</keyword>
  <keyword>intermediate general status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

